NeOnc Technologies Holdings Inc NTHI
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Trading Information
- Previous Close Price
- $3.20
- Day Range
- $3.25–3.30
- 52-Week Range
- $2.50–12.00
- Bid/Ask
- $3.25 / $3.40
- Shares Outstanding
- 28.85M
- Market Cap
- $94.60M
- Volume/Avg
- 2,831 / 211,021
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
NeOnc Technologies Holdings Inc. is a clinical-stage biopharmaceutical company focused on developing novel molecular technologies for the targeted delivery of therapeutics to treat central nervous system diseases. The company is developing drug delivery methods and drug candidates for intracranial malignancies such as gliomas, glioblastoma, and meningioma. Its lead product candidates include NEO100, an intranasal drug delivery therapy for brain cancer patients, and NEO212, an oral chemical conjugate designed to enhance treatment for glioblastoma.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- —
- Total Number of Employees
- 5
- Website
- https://www.neonc.com
Valuation
Metric | NTHI |
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
Metric | NTHI |
|---|---|
Quick Ratio | 0.28 |
Current Ratio | 0.38 |
Interest Coverage | −15.61 |
Quick Ratio
NTHI
Profitability
Metric | NTHI |
|---|---|
Return on Assets (Normalized) | −526.15% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | — |
Return on Assets
NTHI
Biotechnology Industry Comparables
1-Day Chart | Name | Price | Morningstar Rating for Stocks | Capital Allocation | Economic Moat | Market Cap |
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc VRTX | LOCK|S>Wm<Gj | LOCK|dwqbd | $138B | |||
| Moderna Inc MRNA | LOCK|Sjy^@Yy | LOCK|WM> | $96B | |||
| Regeneron Pharmaceuticals Inc REGN | LOCK|lBNNFjf | LOCK|>&yWB | $93B | |||
| argenx SE ADR ARGX | LOCK|#mw$&kV | LOCK|qtV | $58B | |||
| BeOne Medicines Ltd ADR ONC | LOCK|&#>@Cl! | LOCK|wH | $48B | |||
| Royalty Pharma PLC Class A RPRX | LOCK|@zw$ywV | LOCK|$!&@ | $30B | |||
| Incyte Corp INCY | LOCK|!W?!<y | LOCK|r@v | $24B | |||
| BioNTech SE ADR BNTX | LOCK|Fs>LR#K | LOCK|q> | $21B | |||
| Alnylam Pharmaceuticals Inc ALNY | LOCK|pF$wWh | LOCK|%z!V | $21B | |||
| Jazz Pharmaceuticals PLC JAZZ | LOCK|P!x%>H$ | LOCK|Zj | $15B |
United States